Zinc transporters and insulin resistance: therapeutic implications for type 2 diabetes and metabolic disease

J Biomed Sci. 2017 Nov 20;24(1):87. doi: 10.1186/s12929-017-0394-0.

Abstract

Background: Zinc is a metal ion that is essential for growth and development, immunity, and metabolism, and therefore vital for life. Recent studies have highlighted zinc's dynamic role as an insulin mimetic and a cellular second messenger that controls many processes associated with insulin signaling and other downstream pathways that are amendable to glycemic control.

Main body: Mechanisms that contribute to the decompartmentalization of zinc and dysfunctional zinc transporter mechanisms, including zinc signaling are associated with metabolic disease, including type 2 diabetes. The actions of the proteins involved in the uptake, storage, compartmentalization and distribution of zinc in cells is under intense investigation. Of these, emerging research has highlighted a role for several zinc transporters in the initiation of zinc signaling events in cells that lead to metabolic processes associated with maintaining insulin sensitivity and thus glycemic homeostasis.

Conclusion: This raises the possibility that zinc transporters could provide novel utility to be targeted experimentally and in a clinical setting to treat patients with insulin resistance and thus introduce a new class of drug target with utility for diabetes pharmacotherapy.

Keywords: Cell signaling; Glycemic control; Skeletal muscle; Zinc ions.

Publication types

  • Review

MeSH terms

  • Animals
  • Biological Transport
  • Blood Glucose / metabolism*
  • Carrier Proteins / genetics*
  • Carrier Proteins / metabolism
  • Diabetes Mellitus, Type 2 / genetics
  • Diabetes Mellitus, Type 2 / therapy*
  • Homeostasis
  • Humans
  • Insulin Resistance / genetics*
  • Metabolic Diseases / genetics
  • Metabolic Diseases / therapy
  • Mice
  • Rats
  • Zinc / metabolism*

Substances

  • Blood Glucose
  • Carrier Proteins
  • zinc-binding protein
  • Zinc